Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. 1990

S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
Istituto di Neurologia, Università di Verona, Italy.

We investigated the role of complement in the pathogenesis of the demyelinating polyneuropathy that occurs in some patients with IgM monoclonal gammopathy. Seven patients with chronic sensorimotor polyneuropathy and IgM monoclonal gammopathy were examined. In six patients, the monoclonal protein recognized an epitope shared by myelin-associated glycoprotein and two peripheral-nerve glycolipids, whereas in one patient, IgM bound to an unidentified myelin antigen. Direct and indirect immunofluorescence and immunoperoxidase assays showed colocalization along the myelin sheaths of peripheral-nerve fibers of monoclonal protein with complement components C1q, C3d, and C5. In addition, terminal-complement complex that was not associated with S protein was detected in myelin sheaths. It appeared that alterations in myelin geometry caused by the separation of myelin lamellae corresponded to sites at which terminal-complement complex was deposited. We conclude that demyelination in polyneuropathy associated with IgM monoclonal gammopathy may be mediated by complement.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009186 Myelin Sheath The lipid-rich sheath surrounding AXONS in both the CENTRAL NERVOUS SYSTEMS and PERIPHERAL NERVOUS SYSTEM. The myelin sheath is an electrical insulator and allows faster and more energetically efficient conduction of impulses. The sheath is formed by the cell membranes of glial cells (SCHWANN CELLS in the peripheral and OLIGODENDROGLIA in the central nervous system). Deterioration of the sheath in DEMYELINATING DISEASES is a serious clinical problem. Myelin,Myelin Sheaths,Sheath, Myelin,Sheaths, Myelin
D010265 Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. Gammapathy, Monoclonal,Gammopathy, Monoclonal,Monoclonal Gammopathies,Paraimmunoglobulinemia,Paraimmunoglobulinemias,Paraproteinemia,Plasma Cell Dyscrasias,Monoclonal Gammapathies,Monoclonal Gammopathy,Cell Dyscrasia, Plasma,Dyscrasia, Plasma Cell,Monoclonal Gammapathy,Plasma Cell Dyscrasia
D010523 Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. Peripheral Nerve Diseases,Peripheral Neuropathies,PNS (Peripheral Nervous System) Diseases,PNS Diseases,Peripheral Nervous System Disease,Peripheral Nervous System Disorders,Nerve Disease, Peripheral,Nerve Diseases, Peripheral,Neuropathy, Peripheral,PNS Disease,Peripheral Nerve Disease,Peripheral Neuropathy
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003172 Complement C1 The first complement component to act in the activation of CLASSICAL COMPLEMENT PATHWAY. It is a calcium-dependent trimolecular complex made up of three subcomponents: COMPLEMENT C1Q; COMPLEMENT C1R; and COMPLEMENT C1S at 1:2:2 ratios. When the intact C1 binds to at least two antibodies (involving C1q), C1r and C1s are sequentially activated, leading to subsequent steps in the cascade of COMPLEMENT ACTIVATION. C1 Complement,Complement 1,Complement Component 1,C1, Complement,Complement, C1,Component 1, Complement
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5

Related Publications

S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
January 2016, Journal of neuroimmunology,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
September 2009, Journal of neurology, neurosurgery, and psychiatry,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
October 1991, Neuropathology and applied neurobiology,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
September 1995, Journal of neurology, neurosurgery, and psychiatry,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
January 1989, Acta neuropathologica,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
June 2006, Journal of neuroimmunology,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
October 1985, Proceedings of the National Academy of Sciences of the United States of America,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
September 2009, Neurology,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
July 2007, Neurology,
S Monaco, and B Bonetti, and S Ferrari, and G Moretto, and E Nardelli, and F Tedesco, and T E Mollnes, and E Nobile-Orazio, and E Manfredini, and L Bonazzi
August 1988, Neurology,
Copied contents to your clipboard!